JPS6047241B2 - 生理活性物質を分取する方法 - Google Patents
生理活性物質を分取する方法Info
- Publication number
- JPS6047241B2 JPS6047241B2 JP50033528A JP3352875A JPS6047241B2 JP S6047241 B2 JPS6047241 B2 JP S6047241B2 JP 50033528 A JP50033528 A JP 50033528A JP 3352875 A JP3352875 A JP 3352875A JP S6047241 B2 JPS6047241 B2 JP S6047241B2
- Authority
- JP
- Japan
- Prior art keywords
- extraction
- physiologically active
- active substances
- extract
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 32
- 239000013543 active substance Substances 0.000 title claims description 21
- 238000000605 extraction Methods 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 210000000496 pancreas Anatomy 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000012266 salt solution Substances 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
- 239000000284 extract Substances 0.000 description 37
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 19
- 108090000317 Chymotrypsin Proteins 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229960002376 chymotrypsin Drugs 0.000 description 15
- 108090000631 Trypsin Proteins 0.000 description 13
- 102000004142 Trypsin Human genes 0.000 description 13
- 239000012588 trypsin Substances 0.000 description 13
- 229960001322 trypsin Drugs 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 6
- 235000011285 magnesium acetate Nutrition 0.000 description 6
- 239000011654 magnesium acetate Substances 0.000 description 6
- 229940069446 magnesium acetate Drugs 0.000 description 6
- DUUCJSJYISFGCI-WBPXWQEISA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O DUUCJSJYISFGCI-WBPXWQEISA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000001399 Kallikrein Human genes 0.000 description 4
- 108060005987 Kallikrein Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- -1 alkali metal salt Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- SKAWDTAMLOJQNK-UHFFFAOYSA-N 2-acetamido-3-(4-hydroxyphenyl)propanoic acid ethyl ester Chemical compound CCOC(=O)C(NC(C)=O)CC1=CC=C(O)C=C1 SKAWDTAMLOJQNK-UHFFFAOYSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FKMJXALNHKIDOD-LBPRGKRZSA-N TAMe Chemical compound NC(=N)NCCC[C@@H](C(=O)OC)NS(=O)(=O)C1=CC=C(C)C=C1 FKMJXALNHKIDOD-LBPRGKRZSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP50033528A JPS6047241B2 (ja) | 1975-03-22 | 1975-03-22 | 生理活性物質を分取する方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP50033528A JPS6047241B2 (ja) | 1975-03-22 | 1975-03-22 | 生理活性物質を分取する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS51110014A JPS51110014A (enrdf_load_stackoverflow) | 1976-09-29 |
| JPS6047241B2 true JPS6047241B2 (ja) | 1985-10-21 |
Family
ID=12389036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50033528A Expired JPS6047241B2 (ja) | 1975-03-22 | 1975-03-22 | 生理活性物質を分取する方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6047241B2 (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58129031A (ja) * | 1982-01-27 | 1983-08-01 | Mitsubishi Rayon Co Ltd | 導電性樹脂組成物 |
-
1975
- 1975-03-22 JP JP50033528A patent/JPS6047241B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS51110014A (enrdf_load_stackoverflow) | 1976-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10455849B2 (en) | Method for the preparation of a protein peptide, a protein peptide and use thereof | |
| US10575537B2 (en) | Saury Maillard peptide and its preparation method and application | |
| Sealock et al. | Thiamine inactivation by the fresh-fish or Chastek-paralysis factor1 | |
| CN114507702B (zh) | 一种海洋南极磷虾肽及其应用 | |
| JP2018510910A (ja) | 水溶性イガイ抽出物 | |
| CN117568430A (zh) | 一种具有降尿酸活性的南极磷虾肽及其应用 | |
| CN104673865A (zh) | 具有降尿酸作用的秋刀鱼美拉德肽及其制备方法和用途 | |
| Anderson | Some studies on the occurrence of sialic acid in human cartilage | |
| US2134256A (en) | Process of producing and refining organ extracts | |
| US2488564A (en) | Preparation of hyaluronidase | |
| RU2300898C2 (ru) | Способ экстрагирования, очистки и ферментативной модификации альфа`субъединицы 7s-глобулина сои для использования в качестве гипохолестеринемического агента | |
| JPS6047241B2 (ja) | 生理活性物質を分取する方法 | |
| CN114057833B (zh) | 基于减少黑色素沉淀功效的贻贝多肽、多肽粉及制备方法和应用 | |
| JPS6039647B2 (ja) | ガンマ−ｌ−グルタミル−タウリンの単離方法 | |
| JPH06298661A (ja) | 免疫機能抑制剤 | |
| Ito et al. | Milk fat globule membrane substances inhibit mouse intestinal β‐glucuronidase | |
| US4908206A (en) | Extracts of embryonic organs, process for their preparation and pharmaceutical preparation containing them | |
| CN114032271A (zh) | 具有降尿酸功效的牡蛎多肽、多肽粉及制备方法和应用 | |
| US3925158A (en) | Process of manufacturing enzyme preparation rich in lipase | |
| CN114032270B (zh) | 具有美白功效的泥蚶多肽、多肽粉及制备方法和应用 | |
| CN117482126B (zh) | 一种抑制食源性嘌呤吸收的鹅肌肽组合物及其应用 | |
| US4394374A (en) | Thymus gland extracts | |
| JPS6047242B2 (ja) | 生理活性物質を取得する方法 | |
| Astrup et al. | Haemostatic mechanisms in the animal arterial wall | |
| JPH05339168A (ja) | 膵リパーゼおよびコレステロールエステラーゼ阻害剤 |